BioSpectrum Asia Notes O’Melveny is Advising BGI-Shenzhen in Acquisition of Complete Genomics

January 14, 2013 BioSpectrum Asia’s January 14, 2013, article “BGI-Complete deal gets green flag from China” reported that BGI-Shenzhen and Complete Genomics have obtained clearance from China's National Development and Reform Commission regarding BGI's proposed acquisition of Complete Genomics pursuant to the previously announced agreement and plan of merger, dated as of September 15, 2012, among BGI, Beta Acquisition Corporation, and Complete Genomics. The report also noted that O'Melveny & Myers LLP is acting as its legal counsel to BGI-Shenzhen. BioSpectrum Asia’s coverage followed BGI-Shenzhen’s January 11 announcement that it has, through its wholly-owned subsidiary Beta Acquisition Corporation, extended its all cash tender offer to purchase all outstanding shares of common stock of Complete Genomics, Inc. to 12:00 midnight on January 18, 2013.